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Carlos Rodriguez-Galindo Langerhans Cell Histiocytosis (LCH) is a proliferative disorder of activated Langerhans
cells (LC) with highly variable biological behavior and clinical severity. It can affect many
different organs, including the skeleton, skin, lymph nodes, liver, lungs, spleen, and the
hematopoietic and central nervous systems. While the first descriptions were noted at the
beginning of the 20th century, more than one hundred years later, the diagnosis and treatment
of LCH remain have not been fully defined yet. In this issue of Revista Brasileira de
Hematologia e Hemoterapia, Terra Babeto et al.(1) epitomize the ever-changing field in the
understanding, definition and treatment of LCH. In their study, only one third (13 of 37) of
the patients diagnosed with LCH had full confirmation, as defined by positive staining of
CD1a or documentation of Birbeck granules at electron microscopy. However, when the
unconfirmed cases were later reviewed, all patients with available samples were confirmed
to have LCH. Thus, all patients were diagnosed and treated properly based on consistent
clinical and histological features highlighting the seemingly consistent histology of LCH.
In fact, the histopathology of the lesion is uniform regardless of the clinical severity of the
disease and consists of collections of LC, interdigitating cells and macrophages,
accompanied by T lymphocytes with variable numbers of multinucleated giant histiocytes
and eosinophils. In this infiltrative process, the LCs are at the pathogeneic top of this
pyramid, where an intense networking 'dialogue' exists among all the involved cell types.
Historically, Lichtenstein's unification of the three clinical forms of "Histiocytosis X"
(eosinophilic granuloma, Hand-Schüller-Christian disease and Letterer-Siwe disease) was
the culmination of several decades of observations that the proliferating cells in all of these
disorders had the morphology of histiocytes. Although the origin of these cells was obscure
this novel nosological category provided a new way of thinking about these unusual
diseases. Later, electron microscopy revealed the presence of Birbeck granules in LCH
histiocytes. These "racquet-shaped" cytoplasmic organelles are thought to be functionally
important for antigen processing and presentation and appear to be uniquely present in
LCs thus suggesting a shared lineage between these cells and the proliferating cells of
LCH. Cell surface markers also support the pathogenic role of LCs in all forms of LCH. For
example, histiocytes in LCH express CD207, also known as Langerin, which is also expressed
on the surface of LCs and associates with Birbeck granules when it internalizes. However,
Langerin can also be expressed by so-called Langerin-positive dendritic cells in the marginal
zone of the spleen, indicating that it is not solely an LC marker. A more specific marker for
LCs and pathologic histiocytes is CD1a, which as noted by Terra Bebeto et al.(1) has become
the gold standard for LCH diagnostics.
These conflicts in the definition of the disease probably reflect the suboptimal
understanding of the pathogenesis of LCH. Because LCH has been demonstrated to be a
monoclonal disease it may be considered a neoplastic disorder. However, different patterns
of clinical involvement indicate other pathogenetic mechanisms. The occurrence of
spontaneous remission and the benign histopathological appearance of the lesions in LCH
suggest a reactive clonal disorder rather than a malignant process, at least in some cases.
LCs, like other dendritic cells, have a critical role in the immune system and it has been
suggested that LCH could be the result of immune dysregulation. Although no consistent
immunologic abnormalities have been described, there is increasing evidence that LCH
may be the result of an uncontrolled and abnormal proliferation of Langerhans cells
secondary to either immune dysregulation or following exposure to a yet undetermined
stimulus. In order to reconcile the clonal origin of the pathologic Langerhans cells with the
evidence for immune dysregulation, a hypothesis has emerged that proposes that the
monoclonal expansion seen in LCH could represent a host response to chronic antigenic
stimulation. Under conditions of chronic stimulation, dominant clones of dendritic cells
might emerge. These clones might still retain some ability to respond to normal immune
regulatory loops, as exemplified by the therapeutic effect of cyclosporine.
The treatment of LCH over the years has reflected the changing concepts of the
disease process. Indeed the difficulties in developing more effective therapies are linked
to the deficiencies in the understanding of the pathogenesis of LCH. Since the 1970s we
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have known that although many organs can harbor
proliferating LCs, only if organ function were disrupted was
such involvement of prognostic significance. Patients could
then be stratified into different risk categories based on the
extent of their disease and the degree of organ dysfunction.
This is the basis of the treatment of LCH, and the report by
Terra Bebeto et al.(1) exemplifies how these treatment
paradigms can be used to effectively treat those unfortunate
children. Treatment for patients with LCH is currently risk-
adapted; patients with single-system disease confined to a
single site usually require only local therapy or observation
and patients with more extensive disease require systemic
therapy. The best therapeutic option in these cases has not
been defined and responses have been observed with short
courses of steroids with or without the addition of
chemotherapeutic agents. The treatment recommended by
the Histiocyte Society for this group of patients includes a 6-
week induction with prednisone and vinblastine, followed
by continuation treatment with pulses of the same agents
every 3 weeks for approximately 12 months. The prognosis
for this group of patients is usually excellent although
approximately 30% of the patients will experience disease
reactivation that continue to respond to treatment. As noted
earlier and in the report by Terra Babeto et al.,
(1) involvement
of the risk organs carries the worst prognosis. This high-risk
group of patients is characterized by early age at presentation
(usually < 2 years) and different degrees of liver, spleen or
hematopoietic system involvement. Patients respond poorly
to treatment, and the mortality rate is as high as 40%.
The advances in our understanding of the disease and
the risk-stratification therapeutic approaches have slowly
increased the cure rates; survival for children with LCH
exceeds 80%. However, patients with reactivation or chronic
disease may experience severe permanent consequences that
reduce their quality of life; these sequelae are characterized
by fibrosis and degeneration that may affect the brain, lungs
or liver. Thus, cure should not be our only goal; we must
continue to unravel the intricacies underlying the
pathogenesis of this disease and develop better treatments
for those affected.
What was once known as Histiocytosis X continues to
offer challenges to resolve, starting with its own identity.
Decades of research have placed the disease in a context
that floats between the paradigms of the reactive and the
neoplastic disorders and somewhat limited our ability to
approach the diagnosis and treatment of LCH in a more
rational and effective manner. Recent advances have opened
the field to a new and very provocative view of the disease.
Molecular analyses of mouse models and human LCH
samples suggest that the cell of origin in LCH lesions may
not be the epidermal LC itself but a myeloid-derived precursor.
Furthermore, advanced genomic technologies have revealed
the presence of activating, somatic BRAF mutations in the
majority of patient specimens. Together, these observations
have produced a new picture of LCH as a myeloid neoplasm.
These advances are likely to have profound implications for
the use of targeted therapeutics in LCH. We may be back to
the drawing board and back to Histiocytosis X?
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